Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis Journal Article


Authors: Belum, V. R.; Washington, C.; Pratilas, C. A.; Sibaud, V.; Boralevi, F.; Lacouture, M. E.
Article Title: Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
Abstract: Background: The dermatologic adverse events (AEs) of various molecularly targeted therapies are well-described in adult cancer patients. Little has been reported on the incidence and clinical presentation of such AEs in pediatric patients with cancer. To address this gap, we analyzed the dermatologic AEs reported across clinical trials of targeted anticancer therapies in pediatric patients. Procedures: We conducted an electronic literature search (PubMed, American Society of Clinical Oncology annual meetings' abstracts, ClinicalTrials.gov, NCI's Pediatric Oncology Branch webpage) to identify clinical trials involving targeted anticancer therapies that reported dermatologic AEs in their safety data. Studies were limited to the pediatric population, monotherapy trials (oncology), and English language publications. Results: Pooled data from 19 clinical studies investigating 11 targeted anticancer agents (alemtuzumab, rituximab, imatinib, dasatinib, erlotinib, vandetanib, sorafenib, cabozantinib, pazopanib, everolimus, and temsirolimus) were analyzed. The most frequently encountered dermatologic AEs were rash (127/660; 19%), xerosis (18/100; 18%), mucositis (68/402; 17%), and pruritus (12/169; 7%). Other AEs included pigmentary abnormalities of the skin/hair (13%), hair disorders (trichomegaly, hypertrichosis, alopecia, and madarosis; 14%), urticaria (7%), palmoplantar erythrodysesthesia (7%), erythema, acne, purpura, skin fissures, other 'unknown skin changes', exanthem, infection, flushing, telangiectasia, and photosensitivity. Conclusion: This study describes the dermatologic manifestations of targeted anticancer therapy-related AEs in the pediatric population. Since these AEs are often associated with significant morbidity, it is imperative that pediatric oncologists be familiar with their recognition and management, to avoid unnecessary dose modifications and/or termination, and to prevent impairments in patients' quality of life. Pediatr Blood Cancer 2015;62:798-806. © 2015 Wiley Periodicals, Inc.
Keywords: child; sorafenib; bevacizumab; erlotinib; drug safety; monotherapy; skin manifestation; cancer patient; rituximab; antineoplastic agent; imatinib; quality of life; drug eruption; mucosa inflammation; dasatinib; childhood cancer; pediatric; temsirolimus; flushing; pruritus; purpura; rash; clinical study; acne; pazopanib; vandetanib; erythema; hair disease; telangiectasia; hand foot syndrome; alopecia; everolimus; mucositis; photosensitivity; alemtuzumab; urticaria; skin infection; skin fissure; xerosis; targeted therapies; hypertrichosis; clinical trial (topic); molecularly targeted therapy; pigment disorder; adverse events; dermatologic; cabozantinib; human; priority journal; article
Journal Title: Pediatric Blood and Cancer
Volume: 62
Issue: 5
ISSN: 1545-5009
Publisher: Wiley Periodicals, Inc  
Date Published: 2015-05-01
Start Page: 798
End Page: 806
Language: English
DOI: 10.1002/pbc.25429
PROVIDER: scopus
PMCID: PMC4376610
PUBMED: 25683226
DOI/URL:
Notes: Export Date: 4 May 2015 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Mario E Lacouture
    374 Lacouture
  2. Viswanath Reddy Belum
    38 Belum